Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Novo Nordisk’s next obesity battlefront: Winning beyond America

The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around ...

Canada and India now have generic Wegovy. Here’s why the US doesn’t.

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy ...

Doctor issues serious warning over 'most powerful weight loss jab ever' that outperforms Mounjaro and WeGovy

Weight loss injections are more popular than ever but even as science advances, there's no guarantee that they come risk free ...

Retail NZ CEO says Wegovy, tourists, and South Island to thank for 6% spending increase

New Zealand saw a 6% spending increase in retail last quarter with the South Island overtaking the North, likely due to ...
Blockonomi

Novo Nordisk (NVO) Stock Rises as Oral Wegovy Receives European Approval Nod

Novo Nordisk (NVO) stock gains attention as European regulators recommend oral Wegovy approval, marking a first for oral ...

GLP-1 drugs may result in better outcomes for cancer patients, study claims

GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...
Healthline

Wegovy: Semaglutide Reduces Migraine Severity, Especially in Women

A study has found that treatment with Wegovy (semaglutide) led to reduced triptan usage in women. However, no significant ...